Cardiovascular Research Centre, Department of Cardiology, Royal Adelaide Hospital, Adelaide, Australia.
Heart Rhythm. 2011 Apr;8(4):575-82. doi: 10.1016/j.hrthm.2010.12.009. Epub 2010 Dec 8.
It has been suggested that omega-3 polyunsaturated fatty acids (n-3 PUFAs) may prevent the development of atrial fibrillation (AF).
The purpose of this study was to evaluate the impact of these agents on development of the AF substrate in heart failure (HF).
In this study, HF was induced by intracoronary doxorubicin infusions. Twenty-one sheep [7 with n-3 PUFAs treated HF (HF-PUFA), 7 with olive oil-treated HF controls (HF-CTL), 7 controls (CTL)] were studied. Open chest electrophysiologic study was performed with assessment of biatrial effective refractory period (ERP) and conduction. Cardiac function was monitored by magnetic resonance imaging. Atrial n-3 PUFAs levels were quantified using chromatography. Structural analysis was also performed.
Atrial n-3 PUFAs levels were twofold to threefold higher in the HF-PUFA group. n-3 PUFAs prevented the development of HF-related left atrial enlargement (P = .001) but not left ventricular/atrial dysfunction. Atrial ERP was significantly lower in the HF-PUFA group (P <.001), but ERP heterogeneity was unchanged. In addition, n-3 PUFAs suppressed atrial conduction abnormalities seen in HF of prolonged P-wave duration (P = .01) and slowed (P <.001) and heterogeneous (P <.05) conduction. The duration of induced AF episodes in HF-PUFA was shorter (P = .02), although AF inducibility was unaltered (P = NS). A 20% reduction of atrial interstitial fibrosis was seen in the HF-PUFA group (P <.05).
In this ovine HF study, chronic n-3 PUFAs use protected against adverse atrial remodeling by preventing atrial enlargement, fibrosis, and conduction abnormalities leading to shorter AF episodes despite lower ERP.
有研究表明ω-3 多不饱和脂肪酸（n-3 PUFA）可能预防房颤（AF）的发生。
本研究旨在评估这些药物对心力衰竭（HF）中 AF 基质发展的影响。
本研究通过冠状动脉内阿霉素输注诱导 HF。21 只绵羊[7 只为 n-3 PUFA 治疗 HF（HF-PUFA）组，7 只为橄榄油治疗 HF 对照组（HF-CTL）组，7 只为对照组（CTL）组]。开胸电生理研究，评估双房有效不应期（ERP）和传导。通过磁共振成像监测心功能。采用色谱法定量心房 n-3 PUFA 水平。还进行了结构分析。
HF-PUFA 组心房 n-3 PUFA 水平增加了 2 至 3 倍。n-3 PUFA 可预防 HF 相关的左心房扩大（P =.001），但不能预防左心室/心房功能障碍。HF-PUFA 组的心房 ERP 明显降低（P <.001），但 ERP 异质性不变。此外，n-3 PUFA 抑制了 HF 中延长的 P 波持续时间（P =.01）和传导速度减慢（P <.001）和异质性（P <.05）的传导异常。HF-PUFA 组诱发 AF 发作的持续时间较短（P =.02），尽管 AF 可诱发性无改变（P = NS）。HF-PUFA 组心房间质纤维化减少 20%（P <.05）。
在这项绵羊 HF 研究中，慢性 n-3 PUFA 应用可预防心房扩大、纤维化和传导异常，从而导致 ERP 降低的情况下，AF 发作时间缩短。
